Green light committee initiative of the working group on multidrug-resistant tuberculosis of the Stop TB partnership: annual report 2009

Overview

The GLC was established by WHO and partners in 2000 in light of the recognition that lack of access to quality-assured second line anti-tuberculosis drugs (partly as a result of their high price) was one of the major obstacles to implementing MDR-TB management.

The GLC reviews and debates the merit of available scientific evidence, programmatic information and professional experience. Through this activity, the GLC continually updates and refines its own and WHO's understanding and perspective on measures to control DR- TB. The GLC provides its expertise to individuals, donor agencies, bilateral organizations, international organizations, ministries of health and national TB programmes, etc.